SpringWorks Therapeutics SWTX 深 滬
等待開盤 01-28 09:30:00 美东时间
46.99
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 46.99
- 總市值 35.41亿
- 52周最高 62.00
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 28.21
- 委 比 0.00%
- 總股本 7534.90万
- 歷史最高 96.48
- 量 比 0
- 振 幅 0.00%
- 歷史最低 13.60
- 每 手 1
- 風險率 5.87%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
SpringWorks Therapeutics announced that the European Commission has granted marketing authorization for OGSIVEO® (nirogacestat) as the first and only therapy approved in the EU for the treatment of adults with progressing desmoid tumors requiring systemic treatment. The approval is based on the Phase 3 DeFi trial, which demonstrated significant improvements in progression-free survival (PFS), objective response rate (ORR), and patient-reported ou...
2025-08-18 13:10
传默克集团拟发行40亿美元债券 为收购SpringWorks提供资金
据知情人士透露，德国默克集团(Merck KGaA)计划发行约40亿美元的美国投资级债券，为其对SpringWorks Therapeutics的收购提供资金。
2025-08-12 07:57
SpringWorks Therapeutics Receives EC Conditional Marketing Approval For EZMEKLY In Treating NF1-PN Across Pediatric And Adult Patients
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission (EC) granted conditional marketing authorization for EZMEKLY® (mirdametinib) for
2025-07-19 00:14
California Rep. Gilbert Ray Cisneros Sold Over $28K Worth of SpringWorks Therapeutics Inc Ordinary Shares Stock: Here's What You Should Know
An official report on July 10, 2025 reveals Representative Gilbert Ray Cisneros...
2025-07-11 23:00
SpringWorks Therapeutics Completes Merger and Delisting
Springworks Therapeutics ( ($SWTX) ) just unveiled an update. SpringWorks Thera...
2025-07-01 21:08
SpringWorks Merger with Merck Approved by Shareholders
Springworks Therapeutics ( ($SWTX) ) has shared an announcement. On June 26, 20...
2025-06-27 04:53
SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors
The European Medicines Agency (EMA) has recommended the approval of nirogacestat, an oral gamma secretase inhibitor, for the treatment of adults with progressing desmoid tumors in Europe. The European Commission (EC) is expected to make a final decision by the third quarter of 2025. Nirogacestat has already been approved in the U.S. and demonstrated significant benefits in the Phase 3 DeFi trial, including improved progression-free survival and p...
2025-06-20 12:00
SpringWorks Therapeutics Announces Merger with Merck KGaA
An announcement from Springworks Therapeutics ( ($SWTX) ) is now available. On ...
2025-06-16 18:49
